ModifiedHealth NetPolicy CP.PHAR.215

Clinical Policy: Factor VIII (Human, Recombinant)

Defines medical necessity criteria, prior authorization requirements, dosing limits, and coverage limitations for recombinant and human factor VIII products for members with hemophilia A (congenital and acquired) across Commercial, HIM, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyClinical Policy: Factor VIII (Human, Recombinant)

Policy CodePolicy CP.PHAR.215

Change TypeMultiple material revisions and additions (coding, authorization durations, product updates)

Effective DateJun 1, 2016

Next Review DateN/A

Key ActionObtain prior authorization with documentation of diagnosis, hematologist involvement, intended use, weight, and dosing within FDA limits or supporting ITI literature.

SourceLink

POLICY UPDATE CHANGES

Extended initial and continued authorization durations for hemophilia prophylaxis from 6 months to 12 months for HIM Texas.

Added HCPCS code J7214.

For Medicaid and HIM lines of business, continued approval duration revised from 6 months to 12 months for prophylaxis and ITI; for Commercial line, prophylaxis approval durations revised to '6 months or to the member's renewal date, whichever is longer.'

Added Altuviiio to the policy and added Altuviiio coding implications.

Clarified requirement that FVIII activity level or documentation of bleed history only applies to new starts of routine prophylactic therapy.

Removed discontinued product Helixate FS from criteria.

Updated age indication for Jivi from ≥ 12 years to ≥ 7 years and added new 4,000 IU vial strength for Jivi.

Added pathway for off-label use as ITI if regimen is supported by practice guidelines or peer-reviewed literature.

Removed 'life-threatening' from 'life-threatening or serious bleed' criterion.

For continued therapy, member's current weight is only needed if a higher dose is being requested.

>15FVIII products listed requiring prior authorization

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 monthsProphylaxis authorization (HIM/Medicaid)

J7182-J7214HCPCS codes listed

2Distinct diagnosis categories covered

4,000 IUNew Jivi vial strength

Coverage Criteria for Factor VIII Products

Initial Therapy — Covered when ALL of the following are met:

Covered when ALL of the following are met:

Initial Hemophilia A criteria: 1) Diagnosis: congenital hemophilia A (FVIII deficiency) (all products except Obizur) OR acquired hemophilia A (Obizur only); 2) Prescribed by or in consultation with a hematologist; 3) Intended use is one of: control and prevention of bleeding episodes; perioperative management (all products except Obizur); or routine prophylaxis to prevent or reduce frequency of bleeding episodes; 4) For routine prophylaxis requests: product must be one of Advate, Adynovate, Afstyla, Altuviiio, Eloctate, Esperoct, Jivi, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Xyntha; 5) For Jivi: member is >= 7 years of age and previously treated for hemophilia A; 6) Documentation of member body weight in kilograms; 7) Dose meets one of: a) does not exceed the FDA‑approved maximum recommended dose for the relevant indication; or b) if used as part of an immune tolerance induction (ITI) regimen, the dosing regimen is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Prescriber must supply supporting evidence for off‑label ITI dosing.

Continuation Therapy — Covered when ALL of the following are met:

Covered when ALL of the following are met:

Continued Hemophilia A therapy: 1) Member meets one of: a) currently receiving medication via Centene benefit or previously met initial approval criteria; or b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2) Member is responding positively to therapy; 3) If request is for a dose increase, both: a) documentation of member's body weight in kg (required only when requesting a higher dose than previously requested); and b) either i) new dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication; or ii) if used as part of an ITI regimen, dosing regimen is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

For continued therapy, current weight is required only if a higher dose is requested.

Product-specific indication and dosing (selected)

Covered when used for indicated purposes with product-specific dosing per prescribing information (select examples below):

Kogenate FS - Major episodes: Initial 40-50 IU/kg IV, followed by 20-25 IU/kg every 8-24 hours; maximum single dose 50 IU/kg.

Source dosing lines: Kogenate FS perioperative and major episode guidance.

Esperoct - Bleeding episodes: Minor-moderate: 40-65 IU/kg IV (one dose may suffice for minor episodes; additional dose may be given after ~24 hours for moderate); Major: 50-65 IU/kg IV with additional doses approximately every 24 hours as needed. Maximum: ≥12 yrs: 40 IU/kg; <12 yrs: 65 IU/kg.

Includes minor/major episode and age-based maximums.

Advate / Adynovate - Perioperative: Minor surgery: 30-50 IU/kg IV as a single dose within 1 hour and every 12-24 hours (Adynovate: 24 hours) as needed; Major surgery: 40-60 IU/kg IV preop with repeat every 8-24 hours (Advate: every 6-24 hrs if <6 yrs; Adynovate: every 6-24 hrs if <12 yrs). Maximum for minor surgery: 50 IU/kg/dose.

Perioperative dosing guidance for Advate and Adynovate.

Off-label ITI — Policy-level coverage pathways and clarifications

Policy-level coverage pathways and clarifications captured in these chunks include:

Off-label ITI pathway: Off-label use as immune tolerance induction (ITI) is covered when the ITI regimen is supported by practice guidelines or peer‑reviewed literature; prescriber must submit supporting evidence to justify the off‑label ITI regimen.

Added pathway for off‑label ITI; lack of guideline/literature support may lead to denial.

Routine prophylaxis — new starts

Requirements specific to new starts of routine prophylaxis:

New start prophylaxis documentation: Requests for new starts of routine prophylaxis must include the member's FVIII activity level or documentation of bleed history.

Clarified that this documentation requirement applies only to new starts of routine prophylactic therapy.

Authorization duration — Authorization duration rules by line of business:

Authorization duration rules by line of business:

Authorization durations: For Medicaid and HIM lines of business: initial and continued approval durations for prophylaxis and ITI are 12 months. For Commercial line of business: prophylaxis approvals are 6 months or to the member's renewal date, whichever is longer.

1Q 2025 annual review updated durations by line of business.

Von Willebrand disease is specifically listed as a diagnosis for which coverage of factor VIII products is NOT authorized under this policy. Requests for treatment of von Willebrand disease with FVIII products are therefore excluded and may be denied.

Inclusion or exclusion of HCPCS or other billing codes in this clinical policy is provided for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage; providers must reference current professional coding guidance and the payer’s billing rules when submitting claims.

The policy was updated in the 1Q 2026 annual review to remove the discontinued product Helixate FS from the listed criteria. Helixate FS is no longer included as an option in the routine prophylaxis or other product lists within this policy.

Non‑FDA approved indications that are not addressed by this policy are not authorized unless the request includes sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid). Providers should submit supporting evidence per those policies when requesting coverage for off‑label uses.

The document excerpt does not present any explicit criteria that label specific uses of factor VIII products as 'not medically necessary.' Instead, non‑covered indications and requirements for off‑label use are handled via the stated exclusion list and the referenced off‑label use policies.

Product and Billing Codes

Listed products (no codes provided)mixed

NDC/HCPCS not listed

No specific billing codes were listed in this document section

HCPCS codes referencedHCPCS

J7204	Injection, factor VIII, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei, per IU
J7205	Injection, factor VIII fc fusion protein (recombinant), per iu
J7207	Injection, factor VIII (antihemophilic factor, recombinant) pegylated, 1 IU
J7208	Injection, factor VIII, (antihemophilic factor, recombinant), pegylated-aucl, (Jivi), 1 IU
J7209	Injection, factor VIII (antihemophilic factor, recombinant) (Nuwiq), 1 IU
J7210	Injection, factor VIII, (antihemophilic factor, recombinant), (Afstyla), 1 IU
J7214	Injection, factor VIII/von willebrand factor complex, recombinant (Altuviiio), per factor vii IU
J7211	Injection, factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 IU
J7182	Injection, factor VIII, (antihemophilic factor, recombinant), (NovoEight), per IU
J7185	Injection, factor VIII (antihemophilic factor, recombinant) (Xyntha), per IU

1–10 of 13

1/2

Updated HCPCS CodesHCPCS

J7214

HCPCS code added (Injection, factor VIII/von willebrand factor complex, recombinant (Altuviiio), per factor vii IU)

inv-15: Maximum dose per product — product-specific maximum dosing examples

General product maximumMany recombinant and human FVIII products list a maximum single or repeated dose of 50 IU/kg (e.g., Advate/Adynovate, Kogenate FS, Eloctate perioperative limits), per prescribing information.

Esperoct maximumEsperoct: maximum dose differs by age — ≥12 years: 40–50 IU/kg (routine/major episode guidance) with stated maximum 50 IU/kg for some indications; <12 years: maximum 65 IU/kg per product labeling.

Eloctate maximumEloctate: routine prophylaxis maximum 65 IU/kg/dose; perioperative/major-episode maximum guidance lists up to 50 IU/kg every 8 hours until resolved.

Kogenate FS maximumKogenate FS: maximum single dose described as 50 IU/kg (major episodes) and guidance for repeated dosing not to exceed 30 IU/kg for repeated doses in some regimens.

inv-16: Age-based maximum dosing — examples of age-specific dose limits

Prior Authorization, Documentation, and Billing Actions

Prior Authorization

Prior Authorization Required

Prior authorization is required. Providers must document the member's diagnosis, that the prescribing clinician is a hematologist or consulted with one, the intended clinical use (control/prevention of bleeding, perioperative management, or routine prophylaxis), and any additional required clinical information.

Submit supporting clinical documentation such as office/chart notes and laboratory results.
For immune tolerance induction (ITI) requests that are off‑label, include practice guidelines or peer‑reviewed literature supporting the dosing regimen.

Billing Rule

HCPCS‑Coded Prior Authorization

Submit HCPCS-coded prior authorization requests with the appropriate current HCPCS/J‑codes and supporting documentation. Inclusion or exclusion of codes in this policy is informational only and does not guarantee coverage — providers must verify and submit the most up-to-date professional coding guidance with claims.

Background and Scope

Factor VIII replacement products are indicated to control and prevent bleeding, for perioperative management, and for routine prophylaxis in patients with hemophilia A. These products include both human and recombinant factor VIII formulations and may be used for acute bleeding, surgical management, and chronic prophylaxis to reduce bleeding frequency. Obizur (porcine‑sequence recombinant) is indicated specifically for acquired hemophilia A and has dosing and safety considerations distinct from congenital hemophilia products.

Definitions and Abbreviations

inv-31: Bethesda units (BU) used to quantify inhibitor titers

Definition (BU)BU = Bethesda units, the unit used to quantify inhibitor titers to factor VIII.

Location in policyDefined in Appendix A: Abbreviation/Acronym Key (Appendix A).

Clinical useBU values are used to characterize presence and titer of FVIII inhibitors which can affect therapeutic choices (e.g., use of bypassing agents or Obizur).

inv-32: Immune tolerance induction (ITI)

Definition (ITI)ITI = immune tolerance induction, an approach to eradicate anti-FVIII inhibitors by repeated exposure to factor VIII per established regimens.

Off-label ITI pathwayPolicy added pathway: off-label use as ITI is covered when the ITI regimen is supported by practice guidelines or peer-reviewed literature and supporting evidence is submitted.

Policy Summary

PayerHealth Net

PolicyClinical Policy: Factor VIII (Human, Recombinant)

Policy CodePolicy CP.PHAR.215

Change TypeMultiple material revisions and additions (coding, authorization durations, product updates)

Effective DateJun 1, 2016

Next Review DateN/A

Key ActionObtain prior authorization with documentation of diagnosis, hematologist involvement, intended use, weight, and dosing within FDA limits or supporting ITI literature.

SourceLink

On This Page

Eloctate - Routine prophylaxis: 50 IU/kg IV every 4 days for routine prophylaxis (children <6 yrs: 50 IU/kg twice weekly). Maximum dose: 65 IU/kg per dose.

Routine prophylaxis dosing and pediatric adjustment.

Jivi - Routine prophylaxis: ≥12 years: 30-40 IU/kg twice weekly (may adjust to 45-60 IU/kg every 5 days); 7 to <12 years: 60 IU/kg twice weekly; maximum 60 IU/kg per dose.

Includes age-based dosing and maximums for Jivi.

Obizur - Acquired hemophilia A: Dosing for acquired hemophilia A: 200 IU/kg every 4-12 hours; maximum dose 200 IU every 4 hours.

Obizur is for acquired hemophilia A only.

Xyntha / Afstyla / Kovaltry / Novoeight / Nuwiq - Perioperative and prophylaxis examples: Perioperative: minor surgery 15-30 IU/kg IV (varies by product) and major surgery 40-50 IU/kg IV every 8-24 hours; Routine prophylaxis examples include Xyntha 30 IU/kg 3x weekly (or 25 IU/kg every other day in <12 yrs), Afstyla 20-50 IU/kg 2-3x weekly, Novoeight and Nuwiq regimens by age with product-specific maximums (see dosing lines).

Representative perioperative and prophylaxis regimens across listed products.

Esperoct age-based maxEsperoct: ≥12 years — maximum 50 IU/kg; <12 years — maximum 65 IU/kg (routine prophylaxis and bleeding episode guidance).

Eloctate age-based maxEloctate: routine prophylaxis — children <6 years: 50 IU/kg twice weekly (maximum 65 IU/kg/dose noted).

Adynovate (pediatric guidance)Adynovate: pediatric dosing examples include <12 years regimens (e.g., prophylaxis listing of 55 IU/kg IV twice weekly for some pediatric entries) with product-specific maximums (Adynovate max listed up to 70 IU/kg/dose in select entries).

Include the HCPCS code(s) corresponding to the requested product (e.g., J7182, J7185, J7188, J7190, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7214).
Updated HCPCS codes and additions (for example J7214/Altuviiio) have been applied in recent revisions; confirm current code set at time of submission.

Prior Authorization

Authorization Duration Requirements

Authorization durations vary by line of business and indication. Confirm the applicable initial and continued authorization duration when submitting the request.

For Medicaid and HIM lines of business: initial and continued authorization durations for prophylaxis and ITI have been revised to 12 months.
For Commercial line of business: prophylaxis approval durations are generally 6 months or to the member's renewal date, whichever is longer.
Historic changes (e.g., extensions from 6 to 12 months for some lines of business) are documented; verify current durations for the member's plan.

Denial Risk

Non‑Covered Indications Risk

Requests for uses or diagnoses not listed in the policy (including von Willebrand disease) may be denied unless supported per the off‑label use policy for the member's line of business.

Non‑FDA approved indications not addressed in this policy require sufficient documentation of efficacy and safety per the off‑label use policy: CP.CPA.09 (Commercial), HIM.PA.154 (HIM), CP.PMN.53 (Medicaid).
Von Willebrand disease is excluded and typically not authorized under this policy.

Denial Risk

Coding‑Related Denial Risk

Inclusion or exclusion of a code in this clinical policy does not by itself guarantee coverage. Providers should reference the most up‑to‑date coding guidance prior to claim submission to avoid coding‑related denials.

Codes listed are informational; verify code applicability and billing rules at time of submission.
Coding changes and new vial strengths (e.g., Jivi 4,000 IU) have been added in updates — ensure submitted codes match the product strength and formulation.

Documentation Required

Required Documentation

Providers must submit supporting clinical documentation with the prior authorization request to demonstrate that the member meets criteria for approval.

Acceptable documentation includes office/clinic notes, laboratory results, weight in kg, operative notes, bleed history, and hematologist consultation notes.
For routine prophylaxis new‑start requests, include FVIII activity level or documentation of bleed history as applicable (requirement applies to new routine prophylaxis starts only).
For dose escalation or requests for a higher dose during continued therapy, provide the member's current weight (kg).

Documentation Required

Prophylaxis New‑Start Documentation

For routine prophylaxis new‑start requests, documentation of FVIII activity level or a bleed history is required to support the request; this requirement applies only to new routine prophylaxis starts and not to all continued therapy requests.

Requirement clarified to apply only to new routine prophylaxis starts; continuing therapy generally does not require repeat FVIII activity level or bleed history unless other criteria (e.g., dose increase) apply.

Note

Formulary / Label‑Change Routing

If a drug's label has recently changed or the product is non‑formulary, follow the plan‑specific formulary, no‑coverage, or non‑formulary routing policies referenced below to determine coverage and submission requirements.

For formulary drugs: follow the no‑coverage criteria policy CP.CPA.190 (Commercial), HIM.PA.33 (HIM), CP.PMN.255 (Medicaid) as applicable.
For non‑formulary drugs: follow non‑formulary policy CP.CPA.190 (Commercial), HIM.PA.103 (HIM), CP.PMN.16 (Medicaid).

Step Therapy

Step Therapy Note

Step therapy/redirection notes: historical redirection to alternative agents (e.g., Hemlibra) for high factor utilizers was removed; there is no active step therapy requirement documented in the current policy.

Previous redirection to Hemlibra has been removed pending further analysis and is no longer an active step requirement.
Verify current step therapy requirements with the member's line of business prior to submission.

Documentation requirementFor ITI dosing that exceeds FDA limits, prescriber must provide guideline or peer-reviewed literature support as part of prior authorization documentation.

inv-33: Acquired hemophilia A — Obizur indication

IndicationObizur (antihemophilic factor, recombinant, porcine sequence) is indicated for treatment of bleeding episodes in acquired hemophilia A.

Dosing regimenObizur dosing: 200 IU/kg every 4-12 hours (per prescribing information in policy).

Maximum dose guidanceObizur maximum dose documented as 200 IU every 4 hours in the policy dosing table.

inv-34: Serious bleed — revised language replacing 'life-threatening' to 'serious bleed'

Revised terminologyPolicy language was revised to use 'serious bleed' (per WFH guideline in Appendix D) and 'life-threatening' was removed to avoid potential misinterpretation.

Source of changeChange documented in Coding Implications and policy updates noting removal of 'life-threatening' from 'life-threatening or serious bleed'.

Implication for criteriaCriteria referencing bleeding severity now use 'serious bleed' (aligned with WFH guideline) rather than 'life-threatening or serious bleed'.